Reaction
Immune-Mediated Hyperthyroidism reporting signals
As of the last recalculation, Immune-Mediated Hyperthyroidism appears in 236 FAERS reports alongside 8 co-occurring drug terms. The strongest observed disproportionality signal is PEMBROLIZUMAB (PRR 325.1).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Pembrolizumab | 147 | 325.1 | 325.6 |
| Ipilimumab | 62 | 171.5 | 171.7 |
| Nivolumab | 72 | 94.1 | 94.2 |
| Carboplatin | 77 | 78.9 | 78.9 |
| Paclitaxel (Aibumin-Bound) | 51 | 69.5 | 69.6 |
| Paclitaxel | 52 | 59.1 | 59.1 |
| Pemetrexed Disodium | 14 | 34.4 | 34.4 |
| Durvalumab | 6 | 26.7 | 26.7 |